Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663316 | 1.00 | PARP1 (0.49) | PARP1PKMUSP30POLBALDH1A1 | |
| SCHEMBL665125 | 0.94 | PARP1 (0.54) | PARP1PKMPOLBALDH1A1TSHR | |
| SCHEMBL663556 | 0.92 | PARP1 (0.57) | PARP1PKMPOLBALDH1A1TSHR | |
| SCHEMBL666428 | 0.90 | PARP1 (0.56) | PARP1PKMPOLB | |
| SCHEMBL12890049 | 0.80 | PARP1 (0.57) | PARP1PKMPOLB | |
| SCHEMBL663560 | 0.80 | PARP1 (0.57) | PARP1PKMPOLB | |
| SCHEMBL665549 | 0.80 | PARP1 (0.57) | PARP1PKMPOLB | |
| SCHEMBL15458224 | 0.80 | BCHE (0.48) | PKMUSP30POLB | |
| SCHEMBL662773 | 0.77 | PARP1 (0.60) | PARP1PKMUSP30POLB | |
| SCHEMBL12890726 | 0.77 | PARP1 (0.60) | PARP1PKMUSP30POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PKM 450/4885USP30 3434/4885 |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PKM 450/4885USP30 3434/4885 |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PKM 450/4885USP30 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.